Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 mai 2026 22h28 HE | Source: Rush Street Interactive, Inc.

Rush Street Interactive Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders and Concurrent Repurchase of Shares

CHICAGO, May 05, 2026 (GLOBE NEWSWIRE) -- Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”), a leading online casino and sports betting company in the United States and the rest of the Americas,...
04 mai 2026 09h17 HE | Source: ADT Inc.

ADT Announces Pricing of Secondary Public Offering of Common Stock and Concurrent Share Repurchase

ADT announces pricing of the previously announced secondary public offering of 102,000,366 shares of the Company’s common stock.
01 mai 2026 16h01 HE | Source: Avalyn Pharma Inc.

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Avalyn Pharma (Nasdaq: AVLN), a clinical-stage inhaled respiratory therapeutics company, closed its IPO at $345M with full overallotment exercised.
29 avr. 2026 21h00 HE | Source: Avalyn Pharma Inc.

Avalyn Announces Pricing of Upsized Initial Public Offering

BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm...
20 avr. 2026 16h05 HE | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
16 avr. 2026 22h42 HE | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
16 avr. 2026 16h08 HE | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
14 avr. 2026 21h18 HE | Source: TeraWulf Inc.

TeraWulf Announces Pricing of Upsized Common Stock Offering

EASTON, Md., April 14, 2026 (GLOBE NEWSWIRE) -- TeraWulf Inc. (NASDAQ: WULF) (the “Company” or “TeraWulf”) today announced the pricing of its previously announced public common stock offering (the...
10 mars 2026 14h00 HE | Source: Medline Inc.

Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters’ option to purchase additional shares

NORTHFIELD, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its secondary offering of 86,250,000 shares of Medline Inc.’s Class A...
04 mars 2026 20h00 HE | Source: Medline Inc.

Medline Inc. announces pricing of secondary offering of class A common stock

NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline...

Page suivante